Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.
about
Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionAntiretrovirals for reducing the risk of mother-to-child transmission of HIV infectionInfant peripheral blood repetitive element hypomethylation associated with antiretroviral therapy in uteroHaematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trialExposure of Allium cepa root cells to zidovudine or nevirapine induces cytogenotoxic changesFoetal loss and enhanced fertility observed in mice treated with Zidovudine or NevirapineNeurological and developmental effects of HIV and AIDS in children and adolescents.Prenatal exposure to anti-HIV drugs: neurobehavioral effects of zidovudine (AZT) + lamivudine (3TC) treatment in mice.Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infantsAntiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.Follow-up of children exposed to perinatal antiretrovirals.Interventions aimed at decreasing the risk of mother-to-child transmission of HIV infection.Interruption of HBV intrauterine transmission: a clinical study.Antiretroviral exposure and lymphocyte mtDNA content among uninfected infants of HIV-1-infected women.Neurological and psychiatric adverse effects of antiretroviral drugs.Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.Effects of gender on the health and development of medically at-risk infants.Progressive mitochondrial compromise in brains and livers of primates exposed in utero to nucleoside reverse transcriptase inhibitors (NRTIs)Safety of in utero and neonatal antiretroviral exposure: cognitive and academic outcomes in HIV-exposed, uninfected children 5-13 years of age.Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medicationCardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): a cohort studyPerinatal HIV transmission: developing country considerations.Successful techniques for retaining a cohort of infants and children born to HIV-infected women: the prospective P2C2 HIV studyPoint-of-care capillary blood lactate measurements in human immunodeficiency virus-uninfected children with in utero exposure to human immunodeficiency virus and antiretroviral medicationsCardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study).Antiretroviral treatment of maternal HIV infectionGastrointestinal and nutritional complications of human immunodeficiency virus infectionMitochondrial disease in the offspring as a result of antiretroviral therapy.High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothersCase treated with triple therapy of lamivudine, interferon-β and prednisolone for acute exacerbation of chronic hepatitis B during pregnancyGrowth and body composition of uninfected children exposed to human immunodeficiency virus: comparison with a contemporary cohort and United States National StandardsLaboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Antiretrovirals and safer conception for HIV-serodiscordant couplesSafety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants.Incidence of noninfectious conditions in perinatally HIV-infected children and adolescents in the HAART era.Cancer Among Children With Perinatal Exposure to HIV and Antiretroviral Medications--New Jersey, 1995-2010.Cohort Profile: NICHD International Site Development Initiative (NISDI): a prospective, observational study of HIV-exposed and HIV-infected children at clinical sites in Latin American and Caribbean countries.Motor development of infants exposed to maternal human immunodeficiency virus (HIV) but not infected.Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women.
P2860
Q24235500-1DA395D9-1A08-4DAF-90FB-2C97BCF0D056Q24243146-F666BDF6-7D63-498F-A35C-49D318091D95Q28392255-AC44A2DD-1A98-4A7E-B180-3FEFED588B24Q28469195-D0D80FFB-28C2-4BED-80D5-A8C28CBF0FCDQ28540477-D416B4AD-4B7F-4B24-9560-9D8878C2003FQ28543074-EDB206AB-8733-4DA8-B3AA-D338B4594E7AQ30660506-0F2FD6E8-0429-4686-B4DE-119FB147345FQ31910244-602604DB-440C-45B2-9861-DDB59CBA469BQ33747993-F2A4B521-03A0-487C-B3C0-AE757CB0B1F8Q33897042-E58C4F3A-AFBC-4167-9EDE-52D1030FDDE6Q33897617-7BC17826-EC57-48F6-A627-B53AA3E4C09CQ33906773-49BE617F-DF4B-4028-A138-8852AA7CBB5FQ33967082-A972E4D0-8E98-480B-9029-D64E32EFD31CQ33996797-01A634B5-7515-4F78-AE18-EDA8B80AEAEDQ34039419-6FBCCB08-C0A0-4D11-BDCB-25CF9A04F88BQ34181048-6301B02D-5EF4-46E3-8282-EDA945A84850Q34181893-C006BFB7-B9A5-4B5D-B865-67AAE54DF2B0Q34200645-D87A688E-3423-461A-B16B-958DC39C81CCQ34440361-DFF490DF-DD48-4BFC-805B-69F07022E3F2Q34745570-227EF169-B72D-4506-9B88-305FAD724C3AQ34792830-8FC056BF-4291-4ADB-A9ED-5A6832F43C51Q35046412-EB294ADB-957E-430D-A822-8BCDAB7FB111Q35563873-E8865ADE-9E9D-4FD1-A32B-EF810293BBA9Q35622844-4E7E9388-C34E-4D67-8F40-2A377A79466EQ35626381-CBD35B07-CA38-4A46-BEF5-FF99AD75BBBDQ35826189-8772F39B-0CA5-49E1-8249-0941C75840FEQ36233095-EAC94077-E825-44BE-AD19-BCC37771729EQ36446890-418090E2-11CC-4E07-AF96-AB9042A3A61BQ36744874-EA583649-0BE0-42D0-850D-5C07F3594103Q36801132-012AB573-36CC-4684-886B-DD6266D6A187Q36809068-EE8AA522-5410-4948-95D2-663E6791D443Q36851168-C6773873-2B9C-47FC-992B-764F68FC9B33Q36964167-7074E0A1-4C1A-46C7-B644-D2DE7B193983Q37045192-49735A71-2AC3-4F81-9EEA-21F7E3D9AEF1Q37148266-4046C03F-B260-48C3-A496-ED414FAB242BQ37315190-0185E922-0DB9-4165-B7D3-F12A52F74BAFQ37326056-FD01046C-0EB4-463E-A847-97A85C97AAACQ37399025-2D41D4D3-6DF7-44A9-AF31-16F5603E4E59Q37523678-1D584919-7F00-4E74-8531-AE7258FDAFE6Q37598671-AE3882EF-8989-4871-9CBD-DCB831941DDB
P2860
Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. Pediatric AIDS Clinical Trials Group Protocol 219/076 Teams.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Lack of long-term effects of i ...... Group Protocol 219/076 Teams.
@en
Lack of long-term effects of i ...... Group Protocol 219/076 Teams.
@nl
type
label
Lack of long-term effects of i ...... Group Protocol 219/076 Teams.
@en
Lack of long-term effects of i ...... Group Protocol 219/076 Teams.
@nl
prefLabel
Lack of long-term effects of i ...... Group Protocol 219/076 Teams.
@en
Lack of long-term effects of i ...... Group Protocol 219/076 Teams.
@nl
P2093
P356
P1476
Lack of long-term effects of i ...... Group Protocol 219/076 Teams.
@en
P2093
B Cunningham
D E Shapiro
G McSherry
K O'Donnell
P304
P356
10.1001/JAMA.281.2.151
P407
P577
1999-01-01T00:00:00Z